SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly await pivotal Phase 3 IZAR trial data for its inflammatory disease treatment, sonelokimab. The community is focused on the potential for 'best-in-class' efficacy results to catalyze a significant re-rating of the company and trigger a potential acquisition, though managements timeline has created tension among shareholders.

T1 Energy, Inc. engages in providing energy solutions focused on solar module and solar cell manufacturing. It focuses on building an integrated U.S. supply chain for solar and batteries. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is experiencing heightened volatility and intense social media scrutiny as investors weigh the company's long-term potential in domestic solar manufacturing against immediate concerns over project financing and capital expenditure requirements. The community remains deeply divided, with many traders debating whether the stock's recent pullback represents a strategic entry point for long-term growth or a sign of deeper operational risk.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in Japan, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending as market participants closely monitor GameStop's unsolicited acquisition pursuit, fueling significant community debate over the potential for hostile takeover tactics and strategic restructuring. Investors are actively discussing the implications of GameStop's stake, the company's financial capacity to fund the deal, and the broader impact on eBay's leadership and operational future.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple is experiencing heightened volatility as the community remains deeply divided over regulatory delays, with many traders debating whether current price levels offer a long-term accumulation opportunity or signal deeper systemic risks. Sentiment is largely fueled by intense discussions regarding the Clarity Act, the impact of legislative gridlock, and conflicting views on the coin's underlying utility compared to broader market trends.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently facing a mix of bearish sentiment regarding the delayed 'Clarity Act' vote and optimism from institutional accumulation and potential tokenization projects. Traders are actively debating whether this stagnation is a manipulation phase or a critical accumulation opportunity before a broader market rotation.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is seeing heightened investor activity ahead of the upcoming Phase 2 clinical trial readout for ABCL635, a key asset for treating menopause-related symptoms. The community is actively debating the stock's potential for a significant re-rating, focusing on how this trial could validate the company's AI-driven antibody discovery platform and its broader pipeline.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as investors weigh its role as a decentralized AI infrastructure leader against recent volatility and governance concerns surrounding specific subnets. The community remains focused on the project's long-term utility in the evolving AI economy, actively debating its potential as a sovereign alternative to centralized tech giants despite ongoing price fluctuations.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors debate the impact of recent leadership transitions and internal share selling against the company's progress in scaling solid-state battery technology. The community remains deeply divided, balancing concerns over long-term commercialization timelines with speculative interest in potential partnerships within the defense and data center sectors.

Microstrategy Incorporated. The Group's principal activity is to provide business intelligence software that enable companies to analyze raw data stored across their enterprise. The solutions offered by the Group include MicroStrategy 7i, MicroStrategy Intelligence Server, MicroStrategy Web, MicroStrategy Narrowcast Server, MicroStrategy MDX Adapter and MicroStrategy Agent. The Group also offers product support and other services such as technical account management, consulting, education and technical support. These solutions and services are marketed worldwide to the retail, telecommunications, financial services, pharmaceuticals, manufacturing and technology industries. The customers include Bank of Montreal, Ace Hardware Corporation, AT&T, Grange Insurance, AmerisourceBergen Corporation, E.I. Dupont de Nemours and Company, TRX Data Services and US Postal Service.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is heavily trending as investors speculate on institutional accumulation patterns, potential regulatory tailwinds for crypto, and the ongoing impact of Michael Saylor's treasury management strategy. The community is sharply divided between those viewing the stock as a leveraged proxy for Bitcoin upside and others expressing concern over potential share dilution and market volatility.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF is trending as investors react to volatility driven by ongoing geopolitical tensions in the Strait of Hormuz, shifting central bank interest rate expectations, and a broader strategic pivot toward physical gold by sovereign institutions. The community is actively debating the sustainability of the current price action, with many using Elliott Wave analysis and trend rail charts to navigate the sector's recovery while contrasting precious metals against the broader market's performance.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals is trending as investors monitor the commercial launch of NEREUS for motion sickness and debate the company's potential as a buyout target for major pharmaceutical firms. The community is actively discussing the firm's strategic focus on GLP-1 adjunct treatments and pipeline developments while balancing optimism against frustrations over persistent price volatility.

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results PR Newswire WASHINGTON, Aug. 5, 2026 Fanapt Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%Full-year 2026 total revenue...

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 PR Newswire WASHINGTON, July 29, 2026 Conference Call and Webcast to FollowWASHINGTON, July 29, 2026 /PRNewswire...

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab...

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire WASHINGTON, July 15, 2026 WASHINGTON, July...

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PR Newswire WASHINGTON, July 10, 2026 WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda...

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

Equity

The designation covers VCA-894A, Vanda’s investigational treatment for Charcot-Marie-Tooth disease type 2S. 


Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S PR Newswire...

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis PR Newswire WASHINGTON, May 27, 2026 WASHINGTON, May 27, 2026...

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PR Newswire WASHINGTON, May 7, 2026...

$VNDA Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.04 down -126.09% YoY
• Reported revenue of $1.03M down -98.04% YoY
• Vanda Pharmaceuticals Inc. is reiterating its 2026 total revenue guidance of $240 million to $290 million and expects to achieve various financial objectives across its product portfolio throughout the year.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.61	--	--	N/A
Q2 '26	-$0.58	-$1.04	-78.54%	MISSED
Q1 '26	-$0.69	-$0.82	-19.19%	MISSED
Q4 '25	-$0.98	-$2.39	-145.13%	MISSED
Q3 '25	-$0.43	-$0.38	12.31%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings